Growth Hormone
Ipamorelin + CJC-1295 (with DAC)
GHRP (Ipamorelin) paired with the long-acting Drug Affinity Complex form of CJC-1295. The DAC component accumulates over weeks toward a steady GHRH baseline; the GHRP provides acute pulses.
Quick facts
Molecular weight
711 Da
Half-life
2 h
Frequency
daily
Admins / wk
7
Routes
SubQ
Typical dose
100 mcg–300 mcg
Mechanism & positioning
GHRP (Ipamorelin) paired with the long-acting Drug Affinity Complex form of CJC-1295. The DAC component accumulates over weeks toward a steady GHRH baseline; the GHRP provides acute pulses.
Researched for: sustained GHRH baseline, GH-axis support.
Blend composition
| Component | Mass in vial | % of blend | |
|---|---|---|---|
| Ipamorelin | 5 mg | 71.4% | Profile |
| CJC-1295 (with DAC) | 2 mg | 28.6% | Profile |
Reconstitution defaults
Default vial
7 mg
BAC water
2 mL
Concentration
3500 mcg/mL
Doses per vial
~70
Calculate with this peptide
Related peptides in the Growth Hormone class
CJC-1295 (no-DAC)
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
CJC-1295 (with DAC)
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Ipamorelin
A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.
Tesamorelin
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Sermorelin
The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.
Hexarelin
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.